# Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

> **NCT00764907** · PHASE3 · UNKNOWN · sponsor: **University Hospital, Motol** · enrollment: 4000 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** asparaginase
- **DRUG:** cyclophosphamide
- **DRUG:** cytarabine
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** dexamethasone
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** ifosfamide
- **DRUG:** leucovorin calcium
- **DRUG:** mercaptopurine
- **DRUG:** methotrexate
- **DRUG:** prednisone
- **DRUG:** thioguanine
- **DRUG:** vincristine sulfate
- **DRUG:** vindesine

## Key facts

- **NCT ID:** NCT00764907
- **Lead sponsor:** University Hospital, Motol
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2002-11
- **Primary completion:** 2007-10
- **Final completion:** —
- **Target enrollment:** 4000 (ESTIMATED)
- **Last updated:** 2009-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00764907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00764907, "Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00764907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*